It has shown efficacy in animal models of inflammatory bowel disease (IBD), gastric ulcers, and "leaky gut." Systemic anti-inflammatory effects: It appears to dampen inflammatory cascades without the immune-suppressing risks associated with corticosteroids
What this evidence does show: in rat models of acute, surgically induced tendon and ligament injury, BPC-157 administration is associated with improved healing endpoints versus saline controls across the labs that have studied it
This was better than the control group
Unlike oral supplements, injectable vitamin and NAD+ therapies bypass digestion and are delivered directly into the body, allowing for more reliable absorption and clinically guided dosing
BPC157 (5mg | 10mg) Pentadeca studied in gastric mucosal integrity and tissue repair models
This fact has created confusion about BPC-157s VEGF-related activity